Wexford Capital’s ANI Pharmaceuticals ANIP Stock Holding History

Wexford Capital’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,328	Closed	-$39K	–	201
2020 Q4	$39K	Buy	+1,328	New	+$38K	0.01%	261

Other funds holding ANIP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ICOM

Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Wexford Capital's ANIP Position: Q1 2021 in Review

Wexford Capital sold out of ANI Pharmaceuticals (ANIP) in Q1 2021, closing a stake of 1,328 shares — an estimated $39K sold.

Wexford Capital first reported a position in ANIP in Q4 2020 and held it in 1 quarter. The position peaked at $39K in Q4 2020. 106 funds tracked by Wall St. Rank hold ANIP as of Q1 2021.

Wexford Capital reported no remaining ANI Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Wexford Capital sold 1,328 ANI Pharmaceuticals shares in Q1 2021, an estimated $39K.
Wexford Capital first reported a position in ANI Pharmaceuticals in Q4 2020 and held it in 1 quarter.
Wexford Capital's ANI Pharmaceuticals position peaked at $39K in Q4 2020.
106 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.